News

Another tax inversion looming?
Enlarge image

BusinessFranceGermanySwitzerlandUK

Another tax inversion looming?

30.07.2014 - Rumours have it that French Danone wants to sell its medical nutrition business to US drugmaker Hospira for US$5bn in yet another tax inversion deal.

The Financial Times has reported that, “according to people familiar with the situation”, the two companies have negotiated the deal for several weeks now. Until recently, the French consumer group had more than one suitor – German Fresenius and Swiss Nestlé were also interested in the unit. Danone Medical Nutrition makes specialised nutrition that complements drug therapy or can be given via medical devices, such as Fortimel, Nutrini and Flocare.

It is likely that Illinois-based Hospira is interested in the deal in order to move its tax base to Europe, circumventing the comparatively high corporate tax in the US. Compared to US corporate tax of 40 per cent, France only has a 33 per cent tax rate, while in the UK the rate is as low as 21 per cent. For the tax inversion process to work, Danone would have to first spin off its medical nutrition business.

Hospira is not the only US firm that attempts takeovers in order to move their tax base out of the US: Medical device maker Medtronic has recently bought Irish Covidien, and pharma company Abbvie has successfully wooed UK’s Shire. Drug maker Pfizer also tried a takeover with British-Swedish Astrazeneca, but did not succeed. The growing number of US firms that attempt such inversions has the US government worried. US president Obama criticised the companies on CNBC last week, saying: “For you to continue to benefit from that entire architecture that helps you thrive, but move your technical address simply to avoid paying taxes is neither fair, nor is it something that’s going to be good for the country over the long term.”

© european-biotechnology-news.com/um

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/2.html?cHash=807fa298e991d514ff878d4f7a870d11&sort=desc

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.09 SEK12.50%
  • WILEX (D)2.99 EUR6.79%
  • CO.DON (D)2.75 EUR5.77%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.99 EUR251.8%
  • ADDEX (CH)3.82 CHF59.2%
  • 4SC (D)1.45 EUR49.5%

FLOP

  • HYBRIGENICS (F)1.72 EUR-29.5%
  • PROSENSA (NL)9.72 USD-23.4%
  • PROTHENA PLC (IE)17.37 USD-22.1%

TOP

  • SANTHERA (CH)64.00 CHF3022.0%
  • GW PHARMACEUTICALS (UK)426.00 GBP654.0%
  • PAION (D)2.67 EUR292.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.14 EUR-70.6%

No liability assumed, Date: 29.07.2014